GESTONORONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H28O3
Molecular Weight	316.4345
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]

InChI

InChIKey=GTFUITFQDGVJSK-XGXHKTLJSA-N

InChI=1S/C20H28O3/c1-12(21)20(23)10-8-18-17-5-3-13-11-14(22)4-6-15(13)16(17)7-9-19(18,20)2/h11,15-18,23H,3-10H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H28O3
Molecular Weight	316.4345
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/4117437
Curator's Comment: description was created based on several sources, including, http://www.medicamentos.com.mx/DocHTM/22255.htm

Gestonorone is a progesterone analogue indicated for the treatment of benign prostatic hyperplasia and endometrial cancer. The drug is approved in many countries and used under the names Primostat and Depostat.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Benign prostatic hyperplasia 28 Sources: http://www.medicamentos.com.mx/dochtm/18423.htm	Primary		Approved 8429	PRIMOSTAT Approved Use Conservative treatment of benign prostatic hyperplasia and palliative treatment of severe endometrial cancer.
Endometrial cancer 43 Sources: http://www.medicamentos.com.mx/dochtm/18423.htm	Palliative		Approved 8429	PRIMOSTAT Approved Use Conservative treatment of benign prostatic hyperplasia and palliative treatment of severe endometrial cancer.

PubMed

Title	Date	PubMed
Gestronol hexanoate (SH582) and benign prostatic hypertrophy.	1972 Feb	4117436
Clinical trial of gestronol hexanoate (SH582) in benign prostatic hypertrophy.	1972 Feb	4117437
Adjuvant hormonal therapy for stage I endometrial cancer.	2008 Jun	18596890

Patents

Sample Use Guides

In Vivo Use Guide

Slow intramuscular injection of 200 mg every week for 2 to 3 months.

Route of Administration: Intramuscular

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:57:18 UTC 2023` Edited by `admin` on `Fri Dec 15 17:57:18 UTC 2023`
Record UNII	H4G605B7VP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GESTONORONE

Common Name

English

19-NORPREGN-4-ENE-3,20-DIONE, 17-HYDROXY-

Common Name

English

Gestonorone [WHO-DD]

Common Name

English

GESTRONOL

Common Name

English

Classification Tree Code System Code

WHO-ATC

L02AB03